Literature DB >> 17041791

Acute and late genitourinary toxicity of conformal radiotherapy for prostate cancer.

Ryo-ichi Yoshimura1, Masaru Iwata, Hitoshi Shibuya, Yasuyuki Sakai, Kazunori Kihara.   

Abstract

PURPOSE: The aim of this study was to identify predictive factors for genitourinary (GU) toxicity in prostate cancer patients who underwent conformal radiotherapy (CRT).
MATERIALS AND METHODS: In this study we analyzed 154 cases of T1-3N0M0 prostate adenocarcinoma and evaluated the occurrence rate of acute and late GU toxicity and the duration of acute toxicity according to clinical parameters: age, transurethral resection of the prostate prior to CRT, hormone therapy, CRT dose, length of planning target volume (PTV).
RESULTS: Altogether, 41% of the patients developed grade 2 or higher acute GU toxicity. Longer PTV was significantly associated with a higher incidence of acute GU toxicity (>7 cm, 53%; <or=7 cm, 31%; P = 0.003), and hormone therapy prolonged the duration of the toxicity (P = 0.007). Grade 1 or higher late GU toxicity developed in 23% of the patients, and the 2-year late GU toxicity-free survival rate was 79%. Acute GU toxicity was significantly associated with the late GU toxicity-free survival rate (grade 0-1, 88.7%; grade 2-4, 73.2%; P = 0.0007).
CONCLUSION: The length of PTV and hormone therapy were predictive factors for acute GU toxicity. Furthermore, acute GU toxicity was the most important predictive factor for late GU toxicity.

Entities:  

Mesh:

Year:  2006        PMID: 17041791     DOI: 10.1007/s11604-006-0069-3

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  13 in total

1.  Short-course intensity-modulated radiotherapy for localized prostate cancer with daily transabdominal ultrasound localization of the prostate gland.

Authors:  D S Mohan; P A Kupelian; T R Willoughby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-02-01       Impact factor: 7.038

2.  Late GI and GU complications in the treatment of prostate cancer.

Authors:  T E Schultheiss; W R Lee; M A Hunt; A L Hanlon; R S Peter; G E Hanks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-01       Impact factor: 7.038

3.  Fractionation and protraction for radiotherapy of prostate carcinoma.

Authors:  D J Brenner; E J Hall
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-03-15       Impact factor: 7.038

4.  Volume and hormonal effects for acute side effects of rectum and bladder during conformal radiotherapy for prostate cancer.

Authors:  Stephanie T H Peeters; Mischa S Hoogeman; Wilma D Heemsbergen; Annerie Slot; Hans Tabak; Peter C M Koper; Joos V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-04       Impact factor: 7.038

5.  Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.

Authors:  Jeff M Michalski; Kathryn Winter; James A Purdy; Matthew Parliament; Henry Wong; Carlos A Perez; Mack Roach; Walter Bosch; James D Cox
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-07-01       Impact factor: 7.038

6.  Conformal radiotherapy for prostate cancer--longer duration of acute genitourinary toxicity in patients with prior history of invasive urological procedure.

Authors:  K Odrázka; J Vanásek; M Vaculíková; J Petera; M Zouhar; Z Zoul; J Stejskal; Z Skrabková; D Kadecka
Journal:  Acta Oncol       Date:  2001       Impact factor: 4.089

7.  Mechanical assay of consequential and primary late radiation effects in murine small intestine: alpha/beta analysis.

Authors:  J W Peck; F A Gibbs
Journal:  Radiat Res       Date:  1994-05       Impact factor: 2.841

8.  Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial.

Authors:  D P Dearnaley; V S Khoo; A R Norman; L Meyer; A Nahum; D Tait; J Yarnold; A Horwich
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321

9.  Relationship between intestinal fibrosis and histopathologic and morphometric changes in consequential and late radiation enteropathy.

Authors:  C W Langberg; T Sauer; J B Reitan; M Hauer-Jensen
Journal:  Acta Oncol       Date:  1996       Impact factor: 4.089

10.  RTOG 94-06: is the addition of neoadjuvant hormonal therapy to dose-escalated 3D conformal radiation therapy for prostate cancer associated with treatment toxicity?

Authors:  Richard K Valicenti; Kathryn Winter; James D Cox; Howard M Sandler; Walter Bosch; Srinivasan Vijayakumar; Jeff Michalski; James Purdy
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-11-01       Impact factor: 7.038

View more
  3 in total

Review 1.  [Radiotherapy for prostate cancer].

Authors:  Christian Stanek
Journal:  Wien Med Wochenschr       Date:  2007

2.  Toxicity of tomotherapy-based simultaneous integrated boost in whole-pelvis radiation for prostate cancer.

Authors:  Sei Hwan You; Jong Young Lee; Chang Geol Lee
Journal:  Yonsei Med J       Date:  2015-03       Impact factor: 2.759

3.  Acute toxicity and patient-reported symptom score after conventional versus moderately hypofractionated proton therapy for prostate cancer.

Authors:  Takashi Iizumi; Hitoshi Ishikawa; Yuta Sekino; Keiichi Tanaka; Daichi Takizawa; Hirokazu Makishima; Haruko Numajiri; Masashi Mizumoto; Kei Nakai; Toshiyuki Okumura; Hideyuki Sakurai
Journal:  J Med Radiat Sci       Date:  2021-10-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.